Vornorexant
Vornorexant, also known by its developmental code names ORN-0829 and TS-142, is an orexin antagonist medication which is under development for the treatment of insomnia Insomnia, also known as sleeplessness, is a sleep disorder in which people have trouble sleeping. They may have difficulty falling asleep, or staying asleep as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, ... and sleep apnea. It is a dual orexin receptor, orexin OX1 receptor, OX1 and OX2 receptor, OX2 receptor receptor antagonist, antagonist (DORA). The medication is taken oral administration, by mouth. As of June 2021, vornorexant is in Phases of clinical research#Phase II, phase 2 clinical trials for insomnia and Phases of clinical research#Phase I, phase 1 trials for sleep apnea. It is under development by Taisho Pharmaceutical. Vornorexant has a Tmax (pharmacology), time to peak of 2.5hours and a relatively short elimination half-life of 1.3 to 3.3hours. It was desig ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]